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LETTER TO THE EDITOR
Refusal in testicular cancer patients: implications for surveillance
Sir - I read with great interest the paper by Young and
associates (1991) reporting non-seminomatous testicular
patients on a surveillance program after orchiectomy were
less compliant with follow-up than similar chemotherapy
treated patients. This work confirms our earlier suspicion
about non-compliance gleaned from our study of refusal of
therapy in testicular cancer patients (Moul et al., 1989,
1990a).
In that study, a review of 244 testicular cancer patients
treated between 1970 and 1987 from one US centre found
seven patients (2.9%) who refused all or a portion of their
prescribed cancer therapy. All seven died of cancer and six
deaths were directly attributable to refusal since these men
presented with limited retroperitoneal or minimal metastatic
disease. Refusers had a lower educational level, tended to be
under employed, had a limited understanding of their illness,
geneally had dependent personality, and were considered
'under achievers'. One of236 patients (0.4%) refused orchiec-
tomy, one of 148 (0.7%) refused retroperitoneal lymphaden-
ectomy, and all seven patients among 141 treated (5.0%)
refused chemotherapy. Five of these seven refused other
treatments or appropriate follow-up prior to initiating
chemotherapy. Refusals were not simply related to treatment
side-effects; in no case was refusal a short-lived, isolated
incident.
Our experience as well as anecdotal reports by others
(Taylor et al., 1981; Shapiro et al., 1985; Williams et al.,
1987) suggest that refusal in testicular cancer patients is not
rare and may be more common than refusal by patients with
other malignancies. Specifically, for patients offered surveil-
lance after orchiectomy, three deaths are known to have been
caused by refusal or lack of compliance (Moul et al., 1990b).
Refusal and/or noncompliance by testicular cancer patients
may be more common for a number of reasons. These young
and usually otherwise healthy men with this malignancy may
be less able than older patients to acknowledge the threat of
fatal disease. As a coping mechanism, they may hold fast to
their normal 'healthy' routine in denial. This disease also
involves the loss of an external sexual organ at an age when
sexuality is very important which is an address stress for
many patients. The character disorders and lack of education
or understanding identified in our refusers are known to be
additional factors contributing to refusal or non-compliance.
As we stated in 1989 (Moul et al., 1989), the refusals that
we observed gave us concern about 'refusal' manifest by
non-compliance for patients in surveillance programs. Young
and associates now confirm our prior concerns and emphasise
that the ill informed or uneducated patient appears to be at
greater risk. Surveillance policy may be appropriate for some
patients, however, we must realise that testicular cancer
patients may be more prone to non-compliance and extreme
caution is necessary. Education of these patients is critical
and patients exhibiting any degree of unreliability or charac-
ter disorder should not be relied upon to follow a surveil-
lance program.
yours etc,
J.W. Moul
Assistant Professor of Surgery,
Uniformed Services University
of the Health Sciences,
Bethesda, MD 20814;
Attending Urologic-Oncologist
Walter Reed Army Medical Center,
Washington, DC, USA.
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